ImmunoGen Company Profile (NASDAQ:IMGN)

About ImmunoGen

ImmunoGen logoImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company's clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Company's partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Company's collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Company's compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IMGN
  • CUSIP: 45253H10
Key Metrics:
  • Previous Close: $2.82
  • 50 Day Moving Average: $2.92
  • 200 Day Moving Average: $5.06
  • 52-Week Range: $2.53 - $14.22
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.80
  • P/E Growth: 0.00
  • Market Cap: $246.26M
  • Outstanding Shares: 87,326,000
  • Beta: 1.81
  • Net Margins: -239.42%
  • Return on Equity: -530.98%
  • Return on Assets: -54.90%
  • Debt-to-Equity Ratio: -1.22%
  • Current Ratio: 4.15%
  • Quick Ratio: 4.13%
Additional Links:
Companies Related to ImmunoGen:

Analyst Ratings

Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: $10.81 (283.42% upside)

Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
DateFirmActionRatingPrice TargetDetails
8/5/2016Jefferies GroupReiterated RatingBuy$13.00 -> $6.00View Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$9.00 -> $5.00View Rating Details
6/8/2016Cantor FitzgeraldReiterated RatingHoldView Rating Details
6/6/2016Cowen and CompanyReiterated RatingHoldView Rating Details
5/19/2016Royal Bank Of CanadaReiterated RatingSector Perform$7.00View Rating Details
5/5/2016Morgan StanleyReiterated RatingUnderweight$9.00 -> $5.00View Rating Details
5/2/2016Leerink SwannBoost Price TargetMarket Perform$8.00 -> $11.00View Rating Details
4/30/2016Canaccord GenuityReiterated RatingBuyView Rating Details
1/31/2016William BlairReiterated RatingOutperformView Rating Details
11/10/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$24.00View Rating Details
5/6/2015Credit Suisse Group AGInitiated CoverageNeutral$10.00View Rating Details
(Data available from 9/25/2014 forward)


Earnings History for ImmunoGen (NASDAQ:IMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$17.87 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.04)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.15)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.32)($0.83)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ImmunoGen (NASDAQ:IMGN)
Current Year EPS Consensus Estimate: $-1.57 EPS
Next Year EPS Consensus Estimate: $-1.57 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.38)($0.38)($0.38)
Q2 20163($0.38)($0.36)($0.37)
Q4 20161($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)


Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ImmunoGen (NASDAQ:IMGN)
Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 91.63%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016John LambertEVPSell3,889$8.22$31,967.58View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.90View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.00View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.00View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.00View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.60View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.20View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.00View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.00View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.00View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.00View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.81View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ImmunoGen (NASDAQ:IMGN)
News IconKeen Investors Find News on ImmunoGen, Inc. (NASDAQ:IMGN) - Duncan Research (NASDAQ:IMGN) - September 24 at 10:06 AM logoETF’s with exposure to ImmunoGen, Inc. : September 23, 2016 (NASDAQ:IMGN) - September 23 at 5:18 PM
News IconUnder the Microscope, Zeroing in at ImmunoGen, Inc. (NASDAQ:IMGN) - Duncan Research (NASDAQ:IMGN) - September 22 at 3:39 PM
News IconUnder Analyst's Radar: ImmunoGen, Inc. (NASDAQ:IMGN), Advanced Semiconductor Engineering, Inc. (NYSE:ASX) - Newburgh Press (NASDAQ:IMGN) - September 22 at 3:39 PM
News IconBiotech Stocks Worth Chasing: Gilead Sciences Inc. (GILD), ImmunoGen, Inc. (IMGN) - The Independent Republic (NASDAQ:IMGN) - September 22 at 3:39 PM
News IconEarnings According to Analysts for ImmunoGen, Inc. (NASDAQ ... - Frisco Fastball (NASDAQ:IMGN) - September 22 at 8:47 AM
News IconStock in Limelight: Mobile TeleSystems OJSC (NYSE:MBT ... - Newburgh Press (NASDAQ:IMGN) - September 21 at 3:50 PM
News IconImmunoGen, Inc. (IMGN) Receives Hold Rating from Cowen and ... - DailyQuint (NASDAQ:IMGN) - September 21 at 3:50 PM
News IconEarnings Reaction History: ImmunoGen, Inc. (NASDAQ:IMGN) has a 61.54% chance to decline - The Independent Republic (NASDAQ:IMGN) - September 21 at 3:50 PM
News IconPenny Stock Investors Keen on Shares of ImmunoGen, Inc. (NASDAQ:IMGN) - Duncan Research (NASDAQ:IMGN) - September 21 at 3:50 PM
News IconUnder the Microscope: Getting a Closer Look at Shares of ImmunoGen, Inc. (NASDAQ:IMGN) - Duncan Research (NASDAQ:IMGN) - September 19 at 5:40 PM
News Icon2 Biotech Stocks News And Price Trends: ImmunoGen, Inc ... - The Voice Registrar (NASDAQ:IMGN) - September 19 at 5:40 PM
News IconImmunoGen, Inc. (NASDAQ:IMGN) Upgrades/Downgrades Update - Newburgh Press (NASDAQ:IMGN) - September 17 at 10:11 AM logoIMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IMGN) - September 16 at 9:31 AM
News IconTrading the Biotech News: ImmunoGen, Inc. (NASDAQ:IMGN), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - The Voice Registrar (NASDAQ:IMGN) - September 14 at 9:50 AM
News IconHC Stocks in the Rumor= ImmunoGen, Inc. (IMGN), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - share market updates (press release) (NASDAQ:IMGN) - September 14 at 9:50 AM
News IconSell-side Consensus Sees ImmunoGen, Inc. (NASDAQ:IMGN) Going Where Near-Term? - Frisco Fastball (NASDAQ:IMGN) - September 12 at 5:27 PM logoETF’s with exposure to ImmunoGen, Inc. : September 12, 2016 (NASDAQ:IMGN) - September 12 at 5:27 PM
News IconHealthcare Companies in Hotspot: Seattle Genetics, Inc. (NASDAQ:SGEN), ImmunoGen, Inc. (NASDAQ:IMGN) - National Daily Press (NASDAQ:IMGN) - September 9 at 10:21 AM
News IconHC Stocks to watch for= ImmunoGen, Inc. (IMGN), Shire PLC (ADR) (NASDAQ:SHPG) - share market updates (press release) (NASDAQ:IMGN) - September 9 at 10:21 AM
News IconAnalyst Sights on Price Target: ImmunoGen, Inc. (NASDAQ:IMGN) - Post Registrar (NASDAQ:IMGN) - September 8 at 5:31 PM
News IconNarrowing the Lens on ImmunoGen, Inc. (NASDAQ:IMGN) - Duncan Research (NASDAQ:IMGN) - September 7 at 5:46 PM
News IconTwo Biotechnology Names Are Hot: ImmunoGen, Inc. (IMGN), ZIOPHARM Oncology, Inc. (ZIOP) - The Independent Republic (NASDAQ:IMGN) - September 7 at 5:46 PM
News IconOTC Investors Supremely Interested in Shares of ImmunoGen, Inc. (NASDAQ:IMGN) - Duncan Research (NASDAQ:IMGN) - September 6 at 5:36 PM
News IconBiotech Stocks To Put On Your Watch List: ImmunoGen, Inc. (NASDAQ:IMGN), Cerus Corporation (NASDAQ:CERS) - The Voice Registrar (NASDAQ:IMGN) - September 6 at 5:36 PM
News IconImmunoGen, Inc. (NASDAQ:IMGN) Analysts Recommendations and Insider Trading - The Independent Republic (NASDAQ:IMGN) - September 2 at 5:35 PM
News IconHC Stocks to watch for- ImmunoGen, Inc. (NASDAQ:IMGN), Shire PLC (ADR) (NASDAQ:SHPG) - share market updates (press release) (NASDAQ:IMGN) - September 2 at 10:26 AM logoETF’s with exposure to ImmunoGen, Inc. : September 1, 2016 (NASDAQ:IMGN) - September 1 at 5:29 PM logoIMMUNOGEN INC Financials (NASDAQ:IMGN) - September 1 at 8:35 AM logoImmunoGen, Inc. :IMGN-US: Earnings Analysis: 2016 By the Numbers : August 31, 2016 (NASDAQ:IMGN) - August 31 at 10:23 AM
News IconAnalyst Outlook: ImmunoGen, Inc. (NASDAQ:IMGN) - Post Registrar (NASDAQ:IMGN) - August 29 at 5:29 PM
News IconImmunoGen, Inc. (NASDAQ:IMGN) Near to Lift Curtain on September 2016 Earnings - The Voice Registrar (NASDAQ:IMGN) - August 28 at 9:54 AM logoThis Beaten-Down Biotech Could Return 1,500%+: Here’s Why I Won’t Buy It (NASDAQ:IMGN) - August 26 at 5:28 PM logoThis Beaten-Down Biotech Could Return 1,500%+: Here’s Why I Won’t Buy It (NASDAQ:IMGN) - August 26 at 5:28 PM
News IconHot Biotech Stocks Recap: ImmunoGen (NASDAQ:IMGN), Tesaro (NASDAQ:TSRO) - The Voice Registrar (NASDAQ:IMGN) - August 26 at 8:35 AM logoIMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:IMGN) - August 25 at 5:38 PM
News IconTime To Put On The Watch List? - ImmunoGen, Inc. (NASDAQ:IMGN), Mast Therapeutics, Inc. (NYSEMKT:MSTX) - The Voice Registrar (NASDAQ:IMGN) - August 18 at 5:38 PM logoIMMUNOGEN INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NASDAQ:IMGN) - August 18 at 8:39 AM logoIMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:IMGN) - August 17 at 8:40 AM
News IconUpcoming Earnings Report: ImmunoGen, Inc. (NASDAQ:IMGN) - The Voice Registrar (NASDAQ:IMGN) - August 16 at 5:46 PM logoNotable Stock Analyst Ratings: Uranium Energy Corp. (NYSEMKT:UEC), ImmunoGen, Inc. (NASDAQ:IMGN) - Review Fortune (NASDAQ:IMGN) - August 10 at 8:29 AM logoImmunoGen Inc.: ImmunoGen Announces Departure of Chief Development Officer (NASDAQ:IMGN) - August 9 at 5:46 PM logoImmunoGen, Inc. Gets the FDA Green Light (for Its Trial Design) (NASDAQ:IMGN) - August 9 at 4:34 PM logoTargeted Movers: Hemispherx BioPharma, Inc. (NYSEMKT:HEB ... - Street Updates (NASDAQ:IMGN) - August 9 at 8:36 AM logoImmunoGen Announces Departure of Chief Development Officer (NASDAQ:IMGN) - August 9 at 8:36 AM logoThese 2 Lingering Issues Pushed ImmunoGen, Inc. Lower by 10% in July (NASDAQ:IMGN) - August 8 at 11:29 AM logoImmunoGen Inc. (IMGN) Jumps 8.74% on August 05 - (NASDAQ:IMGN) - August 6 at 8:29 AM logoActive Stocks in Pre-Market: ImmunoGen, Inc. (NASDAQ:IMGN ... - Review Fortune (NASDAQ:IMGN) - August 5 at 8:35 AM logoImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences (NASDAQ:IMGN) - August 5 at 8:35 AM
News IconImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly Business Update (NASDAQ:IMGN) - August 4 at 5:55 PM


ImmunoGen (NASDAQ:IMGN) Chart for Sunday, September, 25, 2016

Last Updated on 9/25/2016 by Staff